99mTc-Depreotide Chest SPECT Demonstrates Pulmonary Metastases from Renal Cell Carcinoma

Wei-Jen Shih, MD1,2; Ramon A.L. Romero, MD3,4; Mullet Timothy, MD3,4; and Primo P. Milan, MD5

1Nuclear Medicine Service, VA Medical Center, Lexington, Kentucky; 2Department of Diagnostic Radiology, College of Medicine, University of Kentucky, Lexington, Kentucky; 3Surgical Service, VA Medical Center, Lexington, Kentucky; 4Department of Surgery, College of Medicine, University of Kentucky, Lexington, Kentucky; and 5Radiology Service, VA Medical Center, Lexington, Kentucky

99mTc-Depreotide has been used on single pulmonary nodules to identify somatostatin receptor–positive lung cancer. We report that pulmonary metastases of a 78-y-old man with postradical nephrectomy for renal cell carcinoma were detected by 99mTc-depreotide chest SPECT. Thus, 99mTc-depreotide chest SPECT can be used to diagnose secondary lung cancer, such as pulmonary metastases from renal cell carcinoma with somatostatin receptor–positive tumor, other than primary lung cancer. Depending on whether the 99mTc-depreotide was positive for pulmonary metastases, the patient underwent an appropriate therapy without further invasive procedures.

Key Words: oncology; SPECT; renal; 99mTc; somatostatin receptor


Somatostatin receptor-binding peptide (99mTc-depreotide) has been used in the imaging of suspected malignant tumors in the lung for the evaluation of solitary pulmonary nodules (1,2) and secondary lung cancer (3). This peptide agent has been used to detect breast cancer (4,5). We report that 99mTc-depreotide SPECT demonstrated pulmonary metastases in the case of a patient with renal cell carcinoma to guide the subsequent course of treatment.

CASE REPORT

Seven months after a left radical nephrectomy for renal cell carcinoma, a 78-y-old man was referred for 99mTc-depreotide chest SPECT because a follow-up surveillance chest CT scan showed bilateral upper lobe lesions (Fig. 1). He was incidentally found to have a left renal mass lesion on ultrasonography of the abdomen for gastrointestinal symptoms, most likely a result of gallstones, 9 mo previously, and subsequent CT of the abdomen showed a 6-cm cystic mass in the left kidney. Three weeks later the patient underwent a radical left nephrectomy. The renal tumor was found to be extensive, invading the renal capsule and colonic mesentery. The removed kidney confirmed sarcomatoid renal cell carcinoma. 99mTc-Depreotide lung images (Fig. 2) showed 2 lung lesions in the lungs, one in the right upper lung and another in the left upper lung corresponding to the CT scan of the chest (Fig. 1). Because of the positive findings for lung lesions on SPECT as well as CT, the patient was being worked up for surgical lung resections. Four and one-half weeks later, this patient underwent a wedge lung resection of the right upper lobe; the removed 3.0 × 2.0 × 0.6 cm lesion confirmed metastatic sarcomatoid renal cell carcinoma. Two weeks later, the patient underwent a right upper lobe lobectomy; the results of the pathologic examination also confirmed metastatic renal cell carcinoma, and surgical parenchymal margins were free from tumor cells.

DISCUSSION

One third of patients with a renal cell carcinoma have pulmonary metastases at the time of diagnosis, and one half of those who had a radical nephrectomy for renal cell carcinoma develop pulmonary metastases later (2). Our patient developed pulmonary metastases 9 mo later and fit this category.

99mTc-Depreotide, a relatively new somatostatin analog tumor imaging agent, targets somatostatin receptor–positive tumors. Overexpression of somatostatin receptors has been shown in a multitude of tumors, including breast carcinoma, carcinoid, and renal cell carcinoma (2). Primary breast carcinoma has been detected by this agent (4,5); this agent has also been used to detect non-Hodgkin’s lymphoma (6).
and low-grade lymphoma (7). Although 99mTc-depreotide had not been used in a primary renal cell carcinoma, we described a renal cell carcinoma patient’s pulmonary metastases detected by 99mTc-depreotide chest SPECT.

99mTc-Depreotide has been shown to have almost no gastrointestinal activity because of its predominantly renal excretion (8). Thus, renal activity has been graded as the highest uptake, even higher than the uptake in the liver and spleen on 99mTc-depreotide normal biodistribution (9). Because 99mTc-depreotide is normally localized in the normal renal tissue, both kidneys are normally visualized. Absent visualization of one kidney might indicate renal disease or absence due to surgery, as was the case with our patient whose left kidney is not visualized (Fig. 2A). In addition, overexpression of renal cell carcinoma of 99mTc-depreotide cannot be differentiated from the normal renal tissue; thus, primary renal cell carcinoma is practically undetectable. On the other hand, renal cell carcinoma metastasized to the lung would easily identified on 99mTc-depreotide chest SPECT from the normal lung tissue such shown in Figure 2.

Because pulmonary metastases from renal cell carcinoma are resistant to chemotherapy and radiotherapy—and immunotherapy at present does not considerably improve long-term survival—surgical resection currently is the only effective therapeutic option in renal cell cancer metastatic to the lung (10). Thus, this patient underwent surgical resection.

REFERENCES


